Stimulating the Power of Diversity. Stimulating the Power of Diversity. Stimulating the Power of Diversity. Stimulating the Power of Diversity. Diversity and Function matters The MAB Discovery platform relies on the broad natural immune response and antibody maturation of wild type rabbits combined with B cell cloning. By doing so, we generate a plethora of therapeutic monoclonal antibody candidates which cover various target epitopes, show diverse functional properties and have high affinities requiring no further optimization. It is this diversity generation that we are striving for. And this is enabled by our proprietary, high-performance technology platform. Our Partners About Us. We are a Team of extremely talented and energetic People, who are passionate about pursuing each new Project. MAB Discovery GmbH based in Munich, was founded in 2010 and started operations in 2011 with experienced pharma scientists with a proven track record in drug development. MAB Discovery complies with the highest industrial standards of big pharma, but operates with the flexibility, speed and innovative spirit of a young biotech. The company’s outstanding technology platform offers its collaboration partners access to a large variety of fully functional drug candidates, and a unique route to CMC-compliant humanized mAb’s in 10-12 months. Management DR. STEPHAN FISCHER, CEO Dr. Fischer spent 26 years in R&D at Boehringer-Mannheim/Roche Pharma Research where he focused on the discovery and development of biological based therapeutics.Stephan was a member of the team that developed erythropoietin (NeoRecormon®) and was the scientific and global project leader of the team that developed the thrombolytic reteplase (Retavase®, Rapilysin®) from discovery to launch. Stephan was a member of the global regulatory strategy committee for Biologics and the global task force for biosimilars. As Senior Vice President, Stephan led the Biologics research organization and developed the global strategy for Roche Biologicals with a focus on innovation and new technologies. Stephan received his PhD in Microbiology and conducted his post-doc at the European Molecular Biology Labs. DR. HANS-WILLI KRELL, VP OPERATIONS For over 26 years at Boehringer Mannheim / Roche, Dr. Krell was responsible for the development of high through put assays and screening of new diagnostic and biotechnological enzymes, natural compounds and low molecular weight compounds. More recently, Hans has focused on the discovery and characterization of novel therapeutic antibodies, employing innovative biochemical and cell based screens. In addition, Hans has been actively involved in global project management. Hans (co-) authored more than 40 patent applications and 60 publications. Hans holds a PhD from Freiburg University in biochemistry. Mab Gallery Philosophy RABBIT IMMUNE SYSTEM IS AN UNRIVALED SYSTEM FOR GENERATING ANTIBODY DIVERSITY Rabbit antibodies are known for their excellent affinities and specificities; even generating antibodies to unique epitopes. The explanation for these attributes and the broad diversity of antibodies are the mechanisms employed by the rabbit immune system [read more]. LARGE DIVERSITY REQUIRES HIGH THROUGHPUT TECHNOLOGIES In order to yield the most diverse repertoire of target specific rabbit antibodies, and to allow for a fast identification of the monoclonal antibody with the best functional profile, as many of the IgG expressing B-cell clones as possible are selected and screened in an automated process. 15,000 to 60,000 B-cell clones are isolated and cultured individually per campaign. The secreted monoclonal antibodies can be functionally tested in high throughput assays. SEQUENCE DIVERSITY After sequencing thousands of target-specific antibody genes, it is remarkable that we have never isolated the same sequence from different rabbits immunized with the same immunogen. This supports the assumption that gene conversion produces individual rabbits with a unique gene repertoire for antibodies. Also, the sequence redundancy rate in one individual animal is very low. This is the result of the empirically optimized immunization and sampling protocol. We can guarantee novel sequences from each campaign, a solid basis for IP [read more]. FC ISOTYPE DIVERSITY Function, efficacy and safety profile of therapeutic antibodies can be highly dependent on the antibody isotypes and Fc modifications. Therefore, we introduced special features to allow for flexibility in targeted modification of the antibody’s Fc part [read more]. OUTCOME: UNIQUE ANTIBODIES WITH DIVERSE FUNCTIONALITY Altogether, the above-mentioned factors and procedures result in sets of functional antibodies with unique and diverse functional profiles [read more]. Technology & Innovations Stimulating the Power of Diversity SECRETS OF SUCCESS OF THE MAB DISCOVERY PLATFORM: Wild-type rabbits create very potent antibodies with pM affinities already in an early phase of the immune response. Affinity maturation is not required to isolate potent molecules. Activity screens are possible in B-cell supernatants, including screening for Fc function and cell binding assays. Each rabbit is unique and will create novel antibodies. Very low sequence redundancy within one animal (< 10%). The large number of obtainable leads enables direct humanization and selection for CMC related quality criteria which results in a minimal modality risk for development. In silico analysis of manufacturability as an intrinsic part of lead selection after humanization. Transient recombinant expression selects for well producible molecules. Selected fully humanized MABD antibodies have good drug-like characteristics. IMMUNIZATION MAB Discovery delivers high quality, functional monoclonal antibodies via sophisticated, high-throughput selection of B cells generated by immunization. The immunogen can be a full-length recombinant or partially purified protein preparation, as well as whole cells, DNA or peptide conjugates. The MAB Discovery approach always delivers a vast number of high quality candidates with regard to potency and epitope coverage. MAB Discovery employs a proprietary immunization schedule, enabling a focused and highly successful strategy for each and every individual antigen target. This schedule allows early prediction of project success. The use of wild type rabbits for the immunization and functional B-cell cloning strategy of MAB Discovery suits not only classical target proteins and receptors, but also to a wide variety of more challenging immunogens, e.g. GPCRs, ion channels, carbohydrates, and small sized epitopes. KEY POINTS IMMUNIZATION: Many immunogens possible (Protein, cells, DNA,…) Proprietary immunization schedule Immunogen dependent immunization schedule Different bleeds can be analyzed Prediction of success at an early time point possible B CELL CLONING HIGH-THROUGHPUT SCREENING SEQUENCE ANALYSIS AND HUMANIZATION RECOMBINANT EXPRESSION PROJECT MANAGEMENT LIMS SYSTEM WORKING WITH US News & Events EUROSTARS grants Project Funding for SPARKLE Consortium - MAB Discovery technology will be employed for selection and development of therapeutic antibodies against drug-resistant Klebsiella pneumoniae „DiscoEpiMapp“ – Neuen Antikörpern auf der Spur Cullinan Oncology and MAB Discovery Announce Collaboration to Develop Novel Antibody-Based Therapeutics Collaboration project agreement between MAB Discovery GmbH and BioNTech AG BIOEUROPE MAB Discovery will attend this years BioEurope in Berlin, November 6-8. We will be excited to meeting with you there to discuss your individual development projects. Contact How to find us MAB Discovery GmbH Forstenrieder Straße 8 - 14 82061 Neuried Germany Email: info@mabdiscovery.com Phone: +49 89 990 178-0 Fax: +49 89 990 178-199 Web: www.mabdiscovery.com Arrival BY CAR BY PLANE BY PUBLIC TRANSPORT ContactImprintPrivacy Policy ABOUT US PHILOSOPHY TECHNOLOGY AND INNOVATIONS NEWS AND EVENTS CONTACT +49 89 990 178-0 | info@mabdiscovery.com